Global Cancer Supportive Care Drugs Market

Table of Content

1. INTRODUCTION

1. Study Assumptions and Market Definition

1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

1. Market Overview

2. Market Drivers

1. Large Number of Side-effects Associated with Cancer Treatment

1. Rising Disposable Incomes and Constant Improvements in Healthcare Infrastructure

2. Increasing Prevalence of Cancer

1. Market Restraints

1. Advancements in Targated Therapy Drugs

2. Side Effects of Supportive Care Drugs

3. Stringent Regulatory Process

5. MARKET SEGMENTATION (Market Size by Value – USD million)

1. By Drug Class

5.1.1 Granulocyte Colony-Stimulating Factors (G-CSFs)

5.1.2 ESAs (Erythropoiesis stimulating agent)

5.1.3 Antiemetic

5.1.4 Bisphosphonates

5.1.5 Opioids

5..1.6 NSAIDs (Non Steroidal Anti-Inflammatory Drugs)

1. By Cancer type

1. Breast Cancer

2. Lung Cancer

3. Prostate Cancer

4. Melanoma

5. Other Cancers

2. Geography

5.2.1 North America

5.2.1.1 United States

5.2.1.2 Canada

5.2.1.3 Mexico

5.2.2 Europe

5.2.2.1 Germany

5.2.2.2 United Kingdom

5.2.2.3 France

5.2.2.4 Italy

5.2.2.5 Spain

5.2.2.6 Rest of Europe

5.2.3 Asia-Pacific

5.2.3.1 China

5.2.3.2 Japan

5.2.3.3 India

5.2.3.4 Australia

5.2.3.5 South Korea

5.2.3.6 Rest of Asia-Pacific

5.2.4 Middle East and Africa

5.2.4.1 GCC

5.2.4.2 South Africa

5.2.4.3 Rest of Middle East and Africa

5.2.5 South America

5.2.5.1 Brazil

5.2.5.2 Argentina

5.2.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

6.1 Company Profiles

6.1.1 Amgen Inc.

6.1.2 Helsinn Healthcare

6.1.3 Heron Pharma

6.1.4 Johnson & Johnson

6.1.5 Merck & Co. Inc

6.1.6 Novartis (Sandoz)

6.1.7 F. Hoffmann-La Roche AG

6.1.8 Acacia Pharma Group Plc

6.1.9 Sanofi

6.1.10 Sun Pharmaceutical Industries Ltd.

6.1.11 Celldex Therapeutics

6.1.12 Ipsen Pharma

7. MARKET OPPORTUNITIES AND FUTURE TRENDS